The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sandeep Reddy Kommidi
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mr. Sandeep Reddy Kommidi, a non-promoter shareholder, has sold his entire holding of 27,56,500 equity shares (7.45%) in Oxygenta Pharmaceutical Ltd on May 12, 2025. The transaction was executed off-market as per a Memorandum of Understanding dated September 30, 2024. Post-sale, his holding in the company stands reduced to Nil. The company's total equity share capital remains unchanged at 3,69,83,500 shares of Rs. 10 each.
This is a complete exit by a non-promoter shareholder via an off-market, MOU-based transfer, so it is unlikely to cause direct selling pressure on the stock. However, retail investors should note that a 7.45% stake has changed hands privately, and it may be worth tracking who the buyer is and the price at which this block deal was struck.